Glusod

Active Ingredient:: Empagliflozin
Origin:: EU

Glusod (Empagliflozin)

Q: Is Glusod safe for patients with a history of urinary tract infections?

Patients with recurrent urinary tract infections should be monitored closely, as Glusod can increase the risk of such infections; however, it is not an absolute contraindication.

Q: How often should blood glucose be monitored while taking Glusod?

Blood glucose should be checked regularly according to the treating clinician’s plan, often daily or several times per week, especially when therapy is initiated or dose adjustments are made.

Q: Does Glusod have any impact on blood pressure?

Glusod may cause modest reductions in systolic and diastolic blood pressure due to its osmotic diuretic effect, so blood pressure should be monitored in patients on antihypertensive medications.

Q: What should a patient do if they experience signs of ketoacidosis while on Glusod?

Patients should seek immediate medical attention if they develop symptoms such as nausea, vomiting, abdominal pain, rapid breathing, or unusual fatigue, as these may indicate euglycemic diabetic ketoacidosis.

Q: Are there any dietary restrictions while taking Glusod?

There are no specific dietary restrictions, but patients should maintain adequate hydration and may need to limit excessive carbohydrate restriction, which can increase the risk of ketoacidosis.

Glusod is a prescription medication that contains the active ingredient empagliflozin, an SGLT2 inhibitor used to manage blood glucose. It is supplied in oral form, though specific strength and dosage form details are not disclosed. Marketed in the European Union, Glusod belongs to the antidiabetic therapeutic class and works by reducing renal glucose reabsorption. It is intended for use under medical supervision and regular monitoring by healthcare providers.

Manufacturer / TM Owner

Medochemie Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Glusod (empagliflozin) is indicated primarily for the treatment of type 2 diabetes mellitus in adults, often as part of a comprehensive glycemic control plan.

As monotherapy when diet and exercise alone do not achieve target glycemic levels.
In combination with other oral antidiabetic agents such as metformin, sulfonylureas, or DPP‑4 inhibitors.
As adjunct therapy with basal insulin in patients who require additional glucose lowering.
To improve glycemic control in patients with established cardiovascular risk, as supported by clinical evidence.
May be considered in patients with chronic kidney disease stages 1–3 when appropriate.

Side Effects

The safety profile of Glusod reflects the class effects of SGLT2 inhibitors, with most patients experiencing mild to moderate events, while rare serious reactions may occur.

Common

Increased urinary frequency or volume.
Genital mycotic infections, such as yeast infections.
Thirst and mild dehydration.
Mild gastrointestinal upset, including nausea or abdominal discomfort.
Hypotension, especially in patients on diuretics.

Serious

Ketoacidosis (euglycemic diabetic ketoacidosis).
Severe urinary tract infection or pyelonephritis.
Acute kidney injury or significant decline in renal function.

Precautions & Warnings

When prescribing Glusod, clinicians should evaluate patient-specific factors and monitor for conditions that could increase the risk of adverse outcomes.

Assess renal function before initiation and periodically thereafter; avoid use in severe renal impairment.
Monitor for signs of dehydration, especially in elderly patients or those on diuretics.
Evaluate risk of ketoacidosis, particularly in patients with low carbohydrate intake or acute illness.
Use caution in patients with a history of genital or urinary tract infections.
Review concomitant antihypertensive therapy, as blood pressure may decrease.
Discuss potential pregnancy and lactation considerations, noting limited safety data.

Avoid Interactions

Glusod can interact with several medicines that affect glucose metabolism, renal function, or blood pressure, requiring attention to avoid harmful effects.

Avoid

Concomitant use with potent diuretics or loop diuretics that may exacerbate volume depletion.
Combination with other SGLT2 inhibitors or agents that significantly increase the risk of ketoacidosis.
Strong CYP3A4 inhibitors that could alter empagliflozin metabolism.

Use with caution

Co‑administration with insulin or insulin secretagogues, which may increase hypoglycemia risk; dose adjustments may be needed.
Use alongside ACE inhibitors, ARBs, or NSAIDs, as they can affect renal hemodynamics.
Concurrent use of medications that prolong the QT interval should be monitored, although direct interaction is uncommon.
Caution when combined with GLP‑1 receptor agonists, as additive gastrointestinal effects may occur.
Monitor patients taking NSAIDs for potential renal function changes.

Frequently Asked Questions

Glusod empagliflozin works by inhibiting the sodium‑glucose co‑transporter‑2 (SGLT2) in the proximal renal tubules, which reduces the reabsorption of glucose into the bloodstream and promotes its excretion in urine, thereby lowering blood glucose levels.

By blocking SGLT2, Glusod increases urinary glucose loss, which reduces overall plasma glucose concentrations and contributes to improved glycemic control when used with diet, exercise, and other antidiabetic therapies.

Yes, Glusod is commonly combined with metformin as part of dual oral therapy for type 2 diabetes, provided the patient tolerates both agents and renal function is adequate.

Common side effects include increased urinary frequency, genital yeast infections, thirst, mild dehydration, gastrointestinal discomfort, and occasional low blood pressure, especially in patients taking diuretics.

Glusod should be stopped if the estimated glomerular filtration rate (eGFR) falls below the threshold recommended in the prescribing information (typically <30 mL/min/1.73 m²), or if renal function deteriorates significantly during treatment.

Patients with recurrent urinary tract infections should be monitored closely, as Glusod can increase the risk of such infections; however, it is not an absolute contraindication.

Blood glucose should be checked regularly according to the treating clinician’s plan, often daily or several times per week, especially when therapy is initiated or dose adjustments are made.

Glusod may cause modest reductions in systolic and diastolic blood pressure due to its osmotic diuretic effect, so blood pressure should be monitored in patients on antihypertensive medications.

Patients should seek immediate medical attention if they develop symptoms such as nausea, vomiting, abdominal pain, rapid breathing, or unusual fatigue, as these may indicate euglycemic diabetic ketoacidosis.

There are no specific dietary restrictions, but patients should maintain adequate hydration and may need to limit excessive carbohydrate restriction, which can increase the risk of ketoacidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 01 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.